Dr David Irvine

  • Affiliate (Institute of Cancer Sciences)

email: David.Irvine@glasgow.ac.uk

R321 Level 3, Paul O'Gorman Leukaemia Res Cent, Gartnavel General Hospital, Glasgow G12 0YN

Publications

List by: Type | Date

Jump to: 2020 | 2016 | 2014 | 2013 | 2012 | 2011 | 2010
Number of items: 8.

2020

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

2016

Irvine, D. A. et al. (2016) Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 6, 25476. (doi: 10.1038/srep25476) (PMID:27157927) (PMCID:PMC4860619)

2014

Toofan, P., Irvine, D., Hopcroft, L. , Copland, M. and Wheadon, H. (2014) The role of the bone morphogenetic proteins in leukaemic stem cell persistence. Biochemical Society Transactions, 42(4), pp. 809-815. (doi: 10.1042/BST20140037)

2013

Cramer-Morales, K. et al. (2013) Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood, 122(7), pp. 1293-1304. (doi: 10.1182/blood-2013-05-501072)

2012

Flis, K., Irvine, D., Copland, M. , Bhatia, R. and Skorski, T. (2012) Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leukemia and Lymphoma, 53(12), pp. 2474-2478. (doi: 10.3109/10428194.2012.696313)

Irvine, D.A. and Copland, M. (2012) Targeting hedgehog in hematologic malignancy. Blood, 119(10), pp. 2196-2204. (doi: 10.1182/blood-2011-10-383752)

2011

Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M. and Holyoake, T. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155(1), pp. 128-130. (doi: 10.1111/j.1365-2141.2011.08653.x)

2010

Irvine, D. A., Heaney, N. B. and Holyoake, T. L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data. Blood Reviews, 24(1), pp. 1-9. (doi: 10.1016/j.blre.2009.11.002)

This list was generated on Fri Sep 11 12:30:33 2020 BST.
Jump to: Articles
Number of items: 8.

Articles

Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)

Irvine, D. A. et al. (2016) Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 6, 25476. (doi: 10.1038/srep25476) (PMID:27157927) (PMCID:PMC4860619)

Toofan, P., Irvine, D., Hopcroft, L. , Copland, M. and Wheadon, H. (2014) The role of the bone morphogenetic proteins in leukaemic stem cell persistence. Biochemical Society Transactions, 42(4), pp. 809-815. (doi: 10.1042/BST20140037)

Cramer-Morales, K. et al. (2013) Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood, 122(7), pp. 1293-1304. (doi: 10.1182/blood-2013-05-501072)

Flis, K., Irvine, D., Copland, M. , Bhatia, R. and Skorski, T. (2012) Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leukemia and Lymphoma, 53(12), pp. 2474-2478. (doi: 10.3109/10428194.2012.696313)

Irvine, D.A. and Copland, M. (2012) Targeting hedgehog in hematologic malignancy. Blood, 119(10), pp. 2196-2204. (doi: 10.1182/blood-2011-10-383752)

Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M. and Holyoake, T. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155(1), pp. 128-130. (doi: 10.1111/j.1365-2141.2011.08653.x)

Irvine, D. A., Heaney, N. B. and Holyoake, T. L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data. Blood Reviews, 24(1), pp. 1-9. (doi: 10.1016/j.blre.2009.11.002)

This list was generated on Fri Sep 11 12:30:33 2020 BST.